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Abstract
We consider two approaches to modelling of cell metabolism of 6-mercaptopurine, which is one of
the important chemotherapy drugs used for treating of acute lymphocytic leukemia: kinetic ordinary
differential equations and random Boolean networks, and analyse their interplay with respect to taking
into account ATP concentration as a key parameter of switching between different pathways. It is shown
that Boolean networks, which allows for avoiding complexity of general kinetic modelling, preserve an
opportunity to the reproduction of the principal switching mechanism. To keep a detailed quantitative
measure of the control parameter, a combined Boolean-ODE method is proposed.
1 Introduction
6-mercaptopurine (6-MP) is one of the important chemotherapy drugs used for treating acute lympho-
cytic leukemia (ALL). It belongs to the class of medications called purine antagonists and works by
stopping the growth of cancer cells. 6-MP undergoes extensive metabolic intracellular transformations
that results in the production of thionucleotides and active metabolites, which have cytotoxic and
immunosuppressive properties leading to various acute side-effects as kidney affection, hepatotoxicity,
pancreatitis and neuropathy.
The conversion of 6-MP according the metabolic scheme presented in Fig. 1 involves several small
pathways [1]. The desired pathway results in the formation of 6-Thioguanosine monophosphate (TGMP)
that could be incorporated (via some metabolic transformations) into DNA and RNA leading to the
tumor cell death [2, 3, 4] in the case of successful treatment of ALL. The catabolic pathways reg-
ulated by the enzyme mercaptopurine methyltransferase (TPMT) lead to the production of various
methyl-mercaptopurines affecting purine biosynthesis [2] that leads to treatment failure in most cases
[3]. The transformation (see Fig. 1) of 6-Thioinosine-5’-monophosphate (TIMP) to 6-Thioinosine-5’-
triphosphate (TITP) is also an additional pathway, which results in the accumulation of cytotoxic
products (TITP, TDTP) and slow production of TGMP. Since the realization of each pathway de-
pends on enzymes properties, which are considered as the main regulators of ratio of activated and
inactivated metabolites, then, in particular, a polymorphism in the corresponding genes can lead to
the drug tolerance during ALL therapy [2, 5]. On the other hand, the energetic balance disturbance
connected with the mitochondrial disfunction can play a crucial role in the appearance of side-effects
and treatment failure [6, 7].
Besides experimental studies, enzymes activity in 6-MP metabolism and regulation effects have
been exposed to numerical simulations and mathematical modelling [3, 2, 8]. These detailed semi-
mechanistic models involve various compartments of human organism: from cell to organs to describe
side-effects in dependence on the drug dose that allows for forecasting optimal dose for successful
treatment. However, these models have been more attended to the properties of regulating enzymes
and exclude energy metabolism, which may play a crucial role in the occurrence of side-effects [7].
Moreover, the large scale networks of interacting components require the adjusting of an enormous
1
ar
X
iv
:1
61
1.
00
05
4v
1 
 [q
-b
io.
M
N]
  3
1 O
ct 
20
16
Figure 1: Simplified scheme of 6-MP metabolism. ki/k−i-kinetic constants of forward-back reactions; 6-
MPex, 6-MPin- mercaptopurine outside and inside of cell, TIMP, TITP- 6-Thioinosine-5’-monophosphate
and triphosphate; TXMP- 6-Thioxanthine 5’-monophosphate; TGMP- 6-Thioguanosine monophosphate,
meTGMP- 6-Methylthioguanosine monophosphate; ATP, ADP,AMP - adenosine tri-, di- and monophos-
phates; VD,VPUR,VOUT - common fluxes describing incorporation to DNA and RNA of cells, inhibition of
purine biosynthesis de novo and outflux to environment
number of kinetic constants that prevents understanding of principal mechanisms and key parameters
of switching between the pathways in 6-MP metabolism.
This is why another approach proposed by L. Glass and S. Kaufmann [9] gain popularity, see for a
review of recent state of the art, e.g. [10, 11, 12]: Boolean networks. The Boolean network represents
a graph, whose nodes can take values 0 (inactive) or 1 (active) and the edges are matched to the rules
of Boolean logic. Their evaluation with respect to the previous logical states of nodes determines the
consequent state of the network’s nodes.
Certainly, if ODE-based models are over-complicated, the Boolean networks are often over-simplified.
For example, sometimes their over-simplicity requires introducing tricks, which are artificial to a certain
extent, like over- and under- self- expressed nodes with value 1± 0.5 [13]. This situation calls for some
hybrid models, which should exhibit the best sides of the both approaches [12, 14].
This problem is closely connected with the question about an interplay of ODEs modelling the
scheme of kinetic reactions and Boolean networks simulating activity of reactants. This challenge
induced a number of works, one can mention the pioneering article [15], as well the recent developments
[16, 17]. However, the approaches considered in these works deals with the processes, which exhibit
sharp transitions. In other words, such ODEs corresponds as a rule to the high-order Hill kinetics and
the extraction of fast processes is possible. It is a natural situation for the gene/protein networks, but
the components kinetics of biochemical metabolic networks is more smooth.
Thus, one of the goals of the present work is an attempt to overcome this difficulty utilizing a certain
freedom, which provides probabilistic Boolean networks [18]: a set of Boolean networks, each of them
corresponds to a different pathway, and a choice between them is determined by potential interactions
between underlying biological components and their uncertainties.
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Figure 2: Dependence of the dynamics of metabolic chain on the initial concentration of ATP, red curve
denotes TXMP concentration, blue curve is TIMP concentration
2 Kinetic ODE model
To describe the principal dynamics of 6-MP metabolic transformations and to single out key nodes
of this ”metabolic chain”, we have proposed a model, which describes the simplified kinetic scheme
shown in Fig. 1. The dimensional model does not detalize dynamics of each enzyme but involves ATP
concentration as a key player of the energy metabolism.
As a result, the system of ODE corresponding to the simplified kinetic model can be written as
follows:
d
dt
MPex =− k0MPex,
d
dt
MPin =− (VPUR + k1)MPin + k0MPex + k−1TIMP,
d
dt
TIMP =k1MPin + k−8TITP − (k2 + k7ATP + k−1 + k8PP )TIMP
+ k−2TXMP + k−7TITP ·AMP,
d
dt
TXMP =k2TIMP − k3TXMP ·ATP − k−2TXMP + k−3TGMP ·AMP ·PP,
d
dt
TGMP =k3TXMP ·ATP − (k4 + VD)TGMP − k−3TGMP ·AMP ·PP + k−4meTGMP,
d
dt
meTGMP =k4TGMP − VOUTmeTGMP − k−4meTGMP,
d
dt
TITP =k8TIMP ·PP − k−8TITP + k7TIMP ·ATP − k−7TITP ·AMP,
d
dt
ATP =− k7TIMP ·ATP + k−3TGMP ·AMP ·PP − k3TXMP ·ATP + k−7TITP ·AMP,
d
dt
AMP =− k−3TGMP ·AMP ·PP + k3TXMP ·ATP + k7TIMP ·ATP − k−7TITP ·AMP,
d
dt
PP =− k8TIMP ·PP + k−8TITP − k−3TGMP ·AMP ·PP + k3TXMP ·ATP.
In our simulations, the kinetic constants corresponding to the biophysically relevant dynamics were
determined as k0 = 5 d
−1, k1 = 10 d−1, k2 = 10 d−1, k3 = 5 M−1d−1, k4 = 0.00001 d−1, k7 = 0.01 d−1,
k8 = 0.5 M
−1d−1, k−7 = 1 M−1d−1, k−1 = 0.01 d−1, k−2 = 4 d−1, k−3 = 0.01 M−2d−1, k−4 = 0.1 d−1,
k−8 = 0.01 d−1, VPUR = 0.01 d−1, VD = 0.9 d−1, VOUT = 0.0001 d−1, where M means µM/mL, and d
means days
The initial concentrations were equal to zero for all variables except the fixed value MPex(0) = 0.68
µM/mL and ATP (0), whose value plays a role of a control parameter.
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3 A Boolean network mimicking the key dynamical processes
3.1 Network construction
The simplified metabolic network described above allows the representation in terms of the probabilistic
Boolean network, which consists of five nodes {yi}, i = 1..5 and the threshold-based rule A(αj) for
a choice between possible pathways. The value of the continuous control parameter αj could be
non-stationary in dependence of the iteration’s number j. The correspondence of these nodes to the
metabolites and the transition rules for a parallel update of states are presented in Table 1.
The realisation of this its via Boolean and conditional operators reads as follows (here the states of
nodes are grouped into the matrix y(j, i)):
y(:,1)=[1 0 0 0 0]’;
for j=2:M;
if y(1,j-1)==1;
y(2,j)=1;
end
if alpha>0.5
if (y(2,j-1)==1)|(y(5,j-1)==1)
if alpha<0.75
y(3,j)=y(2,j-1);
y(2,j)=y(5,j-1);
else
y(5,j)=1;
alpha=(1-kappa)*alpha;
end
end
y(4,j)=y(3,j-1);
else
y(3,j)=y(2,j-1);
y(2,j)=1;
end;
end
Here “=”, “==”, and “|” operators denotes the assignment, the equality, and OR respectively. Note
that the code represented above can be evaluated straightforwardly using MATLAB or other software,
which support MATLAB-like syntax (e.g. OCTAVE, FreeMat) if supplied by initial conditions and
a value of the decay parameter. The last one is introduced via the simplest discretization of of the
equation α˙ = −κα via the Euler scheme with the unit time step (i.e. in accordance to the assumed
step of networks nodes updating): αj+1 = (1− κ)αj .
For example, they may be stated as
N=5; % Number of nodes
M=8; % Number of iterations
y=zeros(N,M); % Initializing the matrix
ATP=0.6; % Initial ATP input (control parameter)
kappa=0.1; % The decay parameter value
alpha=ATP;
3.2 Simulation results
The growth of metabolites concentrations occurs sequentially for one node after another along the
metabolic chain (see Fig. 1). It is revealed that TIMP is the key node of the reactions cascade since it
provides two pathways, slow and fast, that also defines the blockage of the slow way interacting with
ATP. Here we can define the concentration of ATP as a key player in the 6-MP metabolism, which
regulates transitions in two main points: the metabolic pathway of TITP production (the chains branch
from TIMP) and the transition TXMP→TGMP.
Simulations of this kinetic model show that small concentrations of ATP lead to the blockage of
metabolic chain in the node TIMP (Fig 2,left). Large concentrations of ATP result in the competition
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between production of TITP (the end product of branch) and TGMP (the product of the chain), see
(Fig 2,middle). The optimal concentration of ATP, which shifts the pathway to higher production of
TGMP is equal to 0.7 µM/mL ((Fig 2,right)).
The same situation can be observed at the simulation of Boolean Networks. Table 2 represents
the results of simulations evaluated for a set of increasing initial values (ATP) of the control parameter
α. They capture all principal features of the dynamics for the simulated network. Note that first two
steps are the same for all cases since the activation of TIMP by 6-MPin is unconditional. The different
pathways are realized during next iterations only.
For ATP=0.2 the dynamics is blocked at the transition from TXMP to TGMP. Instead of the forward
activation, the process goes back reactivating the node corresponding to TIMP. At the same time, since
this reaction is reversible, the reactivation of TXMP occurs, etc. Thus, the system reaches a steady
state, which is reflected in unit values of the nodes y2 and y3 spreading ad infinitum.
The value ATP=0.2 corresponds to the situation, where the pathway TXMP→ TGMP is allowed but
the pathway leading to TITP is blocked. As a result, the transition process is direct and straightforward:
the nodes y1–y4 are activated sequentially during the four sequential iterations. When y4 is activated,
this means that the target substance is released, and all nodes switch off to zeros in absence of a new
influx into y1.
Both the values ATP=0.8 and ATP=0.9 exceed the threshold value α = 0.75. Whence, the pathway
to TITP is available now. It is reflected as y3 = 0 but y5 = 1 at the third iteration, i.e. the pathway
is changed. However, there is a difference in the further time evolution of the network’s states for
these two cases. Namely, the table corresponding to ATP=0.8 demonstrate the activation of y3 (i.e.
the backward transition TITP→ TIMP) during the next iteration and the consequent sequential nodes
activation along the pathway TIMP→ TXMP→ TGMP. On the other hand, these step are delayed
in the case of ATP=0.8: the both 3rd and 4th iterations contains y5 = 1 and yi = 0, i = 1..4 only.
Such a behaviour originates from the introduced non-stationarity of the control parameter α, which
resembles the concentration of ATP. As it was discussed above, the TIMP→ TITP pathway is an
ATP-consuming process. Thus, each iteration corresponding to this pathway diminishes α while it will
cross the threshold α = 0.75 from above. Further, this pathway will be blocked. The cases ATP=0.8
and ATP=0.9 require one and two iterations for this decay of α, respectively. Larger values of ATP will
result in larger delays.
Finally, we should note that the discussed results are quasi-deterministic, since they correspond to
individual realizations. In a general case, i.e. in the strict sense of probabilistic Boolean networks,
one can generate an ensemble of realisations with ATP randomly distributed with respect to some
appropriate probability distribution. Correspondingly, the output will be a distribution of the nodes
values during iterations. But this procedure is out of direct goals of the present work.
4 Discussion
It is known that the methylation of 6-MP resulted in a formation of the intermediate metabolites
occurs at a low concentration of intracellular ATP (0.1 µmol/ml). Simultaneously, the concentrations
TIMP and TXMP remain at a prolonged constant level. At these conditions, a production of the final
metabolite, TGMP, slows down. As a result, the therapeutic efficiency also diminishes but the risk of
toxic action grows since intermediate metabolites of 6-MP inhibit biosynthesis of de novo purines. Thus,
the lowering intracellular ATP pool in T-lymphocytes results in higher toxicity and lower efficiency of
this drug [7, 19].
Our results model an effect of high initial concentration of ATP on the metabolism of 6-MP. They
show that ATP concentrations 0.1 µmol/ml produce high concentrations of the intermediate metabolite
TIMP that indicates an incomplete metabolism of the drug accompanied by a production of TGMP
insufficient for the therapeutic action. Therefore, we suppose that the intensive TIMP formation plays
a role of the marker indicating an accumulation of toxic final metabolites at a high level of intracellular
ATP.
A concentration change of ATP is a key factor for the energy exchange deficit accompanied by the
mitochondrial [21]. This results in decreasing therapeutic effect of drugs during the tumor treatment. It
has been shown the glycolysis inhibition by an attenuation of the glucose consumption cell function leads
to the diminishing of ATP level and, finally, results in tumor cell death. However, the process of energy
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deficiency is invertible since the cell activates another pathway, which supports ATP accumulation, and
the cell will recover its function.
The results obtained using our model argue that the optimal initial ATP concentration is equal to
0.7 µmol/ml. It corresponds to the situation, when 6-MP metabolism is a completed process resulted
in the both production of therapeutically active products and reducing the pool of toxic intermediate
products.
At the administration of cytotoxic drugs according to the protocol BFM ALL 2000 [20], it is
expedient to keep the concentration of intracellular ATP within a middle range to prevent risks of
adverse drugs reactions instead of an artificial inhibition of energy metabolism [21].
The clinical indication of low ATP concentration is acidosis by lactates accumulation [21]. This leads
to the mitochondrial dysfunction and an additional toxic effect. Higher ATP concentrations inhibit
glycolysis resulting in a glucose accumulation, glycose tolerance, and, indirectly, in the cardiomyopathy
development [22].
Thus, we hypothesize that the maintenance of ATP intermediate level is a necessary condition to
reach a complete therapeutic effect and diminish toxicity of a chemotherapy process.
5 Conclusion and Outlooks
In this work, we have analysed the dynamic behaviour of metabolic pathways of 6-mercaptopurine
with a focus on the revealing a key parameter, which switches between two principal “branches”,
slow and fast one. The results of simulations based on the system of ordinary equations indicate
that ATP is the desired key player in the 6-MP metabolism. This conclusion is supported by a
number of phenomenological observations presented in the modern biomedical literature and allows for
quantitative clarifying the underlying processes.
Basing on the results of ODE modelling, we have reformulated the problems in terms of the proba-
bilistic Boolean networks. This approach is much more simpler in realization since it does not require a
knowledge of multiple kinetic parameters but, in the same time, adequately reproduces the key details
of switching principal dynamic regimes as a choice between different possible pathways. Therefore,
it can be scaled to more detailed picture of metabolites interactions in future research of the studied
process.
We also need to highlight the crucial feature introduced into a construction of the network: a non-
stationary continual parameter, which governs the switching process. Such an approach, which has
demonstrated its effectiveness in the considered case study, opens new perspectives for “hybridising”
of continual (ODE-based) and discrete (Boolean) approaches to metabolic modelling. In contrast to
previous works [15, 16, 17], which considered Boolean networks only as a limiting case of continual-
time kinetic processes (in fact, as a mimicking of switching between unstable stationary state by nodes
activity), the introduction of non-stationarity into the probabilistic parameter allows the consideration
of smoother transitions, and, in principle, even an activity of small sub-networks with a small number
of kinetic constants considered as building blocks for a large Boolean network.
Acknowledgement
The work is supported by the Grant no. 14.575.21.0073, code RFMEFI57514X0073 of the Ministry of
Education and Science of the Russian Federation
References
[1] Cheok M.H., Pottier N., Kager L.,Evans W.E. (2009). Pharmacogenetics in acute lymphoblastic
leukemia. Seminars in hematology, WB Saunders, 46(1), 39-51.
[2] Panetta J.C., Evans W.E., Cheok M.H. (2006). Mechanistic mathematical modelling of mercap-
topurine effects on cell of human acute lymphoblastic leukaemia cells. British Journal of Cancer,
94, 93-100
6
[3] Jayachandran D., Rundell A.E., Hannemann R.E., Vik A.T., Ramkrishna D. (2014). Optimal
Chemotherapy for Leukemia: A Model-Based Strategy for Individualized Treatment. PLOS one,
9(10), 1-18
[4] Hedeland R.L., Hvidt K., Nersting J., Rosthj S., Dalhoff K., Lausen B., Schmiegelow K. (2010).
DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute
lymphoblastic leukaemia and non-Hodgkin lymphoma. (2010). Cancer Chemother Pharmacol.,
66(3), 485-91.
[5] Dorababu P., Nagesh N.,Linga V.G., Gundeti S.,Kutala V.F., Reddanna P., Digumarti R. (2012).
Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate
pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with
acute lymphoblastic leukemia. Eur J Clin Pharmacol, 68, 379-387
[6] Daehn I., Brem R., Barkauskaite E., Karran P. (2011). 6-Thioguanine damages mitochondrial
DNA and causes mitochondrial dysfunction in human cells. FEBS Letters, 585, 3941-46
[7] Ferna´ndez-Ramos, A. A., Poindessous, V., Marchetti-Laurent, C., Pallet, N., Loriot, M. A. (2016).
The effect of immunosuppressive molecules on T-cell metabolic reprogramming. Biochimie, 127,
23-36.
[8] Ogungbenro K., Aarons L. (2014). Physiologically based pharmacokinetic modelling of methotrex-
ate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with
methotrexate. J Pharmacokinet Pharmacodyn., 41, 173185
[9] Glass, L., Kauffman, S. A. (1973). The logical analysis of continuous, non-linear biochemical
control networks. Journal of Theoretical Biology, 39(1), 103-129.
[10] Karlebach, G., Shamir, R. (2008). Modelling and analysis of gene regulatory networks. Nature
Reviews Molecular Cell Biology, 9(10), 770-780.
[11] Wang, R. S., Saadatpour, A., Albert, R. (2012). Boolean modeling in systems biology: an overview
of methodology and applications. Physical biology, 9(5), 055001.
[12] Le Nove´re, N. (2015). Quantitative and logic modelling of molecular and gene networks. Nature
Reviews Genetics, 16(3), 146-158.
[13] Davidich, M. I., Bornholdt, S. (2013). Boolean network model predicts knockout mutant pheno-
types of fission yeast. PLoS One, 8(9), e71786.
[14] Fisher J., Henzinger, T. A. (2007). Executable cell biology. Nature biotechnology, 25(11), 1239-
1249.
[15] Davidich, M., Bornholdt, S. (2008). The transition from differential equations to Boolean networks:
a case study in simplifying a regulatory network model. Journal of Theoretical Biology, 255(3),
269-277.
[16] Sto¨tzel, C., Ro¨blitz, S., Siebert, H. (2015). Complementing ODE-based system analysis using
Boolean networks derived from an Euler-like transformation. PloS One, 10(10), e0140954.
[17] Menini, L., Possieri, C., Tornambe´, A. (2016). Boolean network representation of a continuous
time system and finite horizon optimal control: application to the single gene regulatory system
for the lac operon. International Journal of Control, DOI:10.1080/00207179.2016.1186289.
[18] Shmulevich, I., Dougherty, E. R., Kim, S., Zhang, W. (2002). Probabilistic Boolean networks: a
rule-based uncertainty model for gene regulatory networks. Bioinformatics, 18(2), 261-274.
[19] Valente, M. J., Arajo, A. M., de Lourdes Bastos, M., Fernandes, E., Carvalho, F., de Pinho,
P. G., Carvalho, M. (2016). Characterization of hepatotoxicity mechanisms triggered by designer
cathinone drugs (-keto amphetamines). Toxicological Sciences, doi: 10.1093/toxsci/kfw105.
[20] Flohr, T., Schrauder, A., Cazzaniga, G. et al. (2008). Minimal residual disease-directed risk strat-
ification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene
rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute
lymphoblastic leukemia. Leukemia, 22, 771-782.
[21] Beuster, G., Zarse, K., Kaleta, C., Thierbach, R., Kiehntopf, M., Steinberg, P., Shuster, S., Ristow,
M. (2011). Inhibition of alanine aminotransferase in silico and in vivo promotes mitochondrial
metabolism to impair malignant growth. Journal of Biological Chemistry, 286(25), 22323-22330.
[22] Guertl, B., Noehammer, C., Hoefler, G. (2000). Metabolic cardiomyopathies. International Journal
of Experimental Pathology, 81, 349-372.
7
Node Metabolite Rules of interactions and updating
y1 6MPin Starting node activated, when 6-mercaptopurine enters the cell.
It activates TIMP and then will be deactivated.
y2 TIMP This node is activated by 6MPin or by TITP and can activate
nodes TXMP or TITP in dependence on a chosen pathway (the
choice is governed by the variable α); it is deactivated after this.
y3 TXMP This node is activated by TIMP and can activate TGMP or
TIMP in dependence on a chosen pathway (the choice is gov-
erned by the variable α); it is deactivated after this.
y4 TGMP This node indicate the target output, is activated by TXMP
and deactivated after the completed output.
y5 TITP This node is activated by TIMP within one of possible pathways
and activate TIMP; it is deactivated after this.
α ATP The continual parameter, which governs a choice of pathways
by as follows: if α < 0.5, then then the irreversible ac-
tivation TXMP→TGMP is chosen; the reversible transition
TXMP⇀↽TGMP holds otherwise; if α < 0.75 the pathway
through TXMP is chosen, the pathway through TITP holds
otherwise. The parameter α is non-stationary and satisfies the
decay kinetics α˙ = −κα if the process goes through the TIMP
pathway.
Table 1: The nodes and transition rules for the considered Boolean network
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ATP=0.2
j 1 2 3 4 5 6 7
y1 1 0 0 0 0 0 0
y2 0 1 1 1 1 1 1
y3 0 0 1 1 1 1 1
y4 0 0 0 0 0 0 0
y5 0 0 0 0 0 0 0
ATP=0.6
j 1 2 3 4 5 6 7
y1 1 0 0 0 0 0 0
y2 0 1 0 0 0 0 0
y3 0 0 1 0 0 0 0
y4 0 0 0 1 0 0 0
y5 0 0 0 0 0 0 0
ATP=0.8
j 1 2 3 4 5 6 7
y1 1 0 0 0 0 0 0
y2 0 1 0 1 0 0 0
y3 0 0 0 0 1 0 0
y4 0 0 0 0 0 1 0
y5 0 0 1 0 0 0 0
ATP=0.9
j 1 2 3 4 5 6 7
y1 1 0 0 0 0 0 0
y2 0 1 0 0 1 0 0
y3 0 0 0 0 0 1 0
y4 0 0 0 0 0 0 1
y5 0 0 1 1 0 0 0
Table 2: The evolution of network states for different various values of the control parameter.
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